2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 12, 2019

9:00AM-11:00AM: Abstract Number: 2045

RNA Sequencing of Plasma and Urine-derived Extracellular Vesicles from Lupus Nephritis Patients Identifies Disease-associated Small RNA Signatures and Putative Therapeutic Targets

SLE – Etiology & Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 2238

Role of Clinical Impact, Disease-specific Knowledge and Beliefs About Medication on Therapeutic Adherence in Rheumatoid Arthritis: An Integrative Structural Equation Modeling Approach

Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences

9:00AM-11:00AM: Abstract Number: 2154

Role of Insulin Resistance and Inflammation on Resting Energy Expenditure in Patients with Rheumatoid Arthritis

Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

9:00AM-11:00AM: Abstract Number: 1927

Role of Mitochondrial DNA from OA Patients in Cellular Apoptosis, Senescence and Autophagy

Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 2420

Role of T Follicular Helper Cells and T Peripheral Helper Cells in the Activation of B Cells in Sjögren Syndrome

Sjögrenʼs Syndrome – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 2424

RORγt Antagonist Attenuates Experimental Sialadenitis Like Sjögren’s Syndrome via Inhibition of CD25 Expression on CD4+ T Cells

Sjögrenʼs Syndrome – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: L12

Safety and Efficacy of Olokizumab in a Phase III Trial of Patients with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate – CREDO1 Study

Late-Breaking Abstracts ePoster

9:00AM-11:00AM: Abstract Number: 2093

Safety of Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su, Shingrix) Among Patients with Autoimmune Inflammatory Diseases

Infection-Related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 2375

Safety of Baricitinib Under Clinical Settings in Patients with Rheumatoid Arthritis, Using Data from All-Case Post-marketing Surveillance and Spontaneous Reports

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2360

Safety of Biological DMARD in Patients with Interstitial Lung Disease from a Chilean Cohort of Patients with Rheumatoid Arthritis

RA – Treatments Poster III: Safety and Outcomes

9:00AM-11:00AM: Abstract Number: 2529

Safety of Chloroquine and Hydroxychloroquine During Pregnancy: A Systematic Review and Meta-Analysis

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2152

Safety of Immune Checkpoint Inhibitors in Patients Treated for Cancer with Pre-existing Autoimmune Diseases

Miscellanous Rheumatic & Inflammatory Disease Poster III: Autoimmune Conditions and Therapies

9:00AM-11:00AM: Abstract Number: 2547

Safety Results of 50% Enrollment from a Multicenter, Randomized, Double‑blind, Placebo‑controlled Study to Assess the Efficacy and Safety of Repository Corticotropin Injection in Patients with Systemic Lupus Erythematosus Despite Moderate‑dose Corticosteroid Use

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2530

Safety, Pharmacokinetics, and Pharmacodynamics of a Lyophilized Drug Product of KZR-616, a Selective Inhibitor of the Immunoproteasome

SLE – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2574

Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of BIIB059, a Monoclonal Antibody Targeting BDCA2 Following Administration of Subcutaneous Single Doses in Japanese Healthy Volunters

SLE – Clinical Poster III: Treatment

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].